



ASX Release

14 November 2018

**ZELDA THERAPEUTICS LIMITED**  
ACN 103 782 378

Level 26  
140 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
enquiries@zeldatherapeutics.com  
www.zeldatherapeutics.com

**Contacts:**

**Zelda Therapeutics**

Dr Richard Hopkins  
Managing Director  
+61 405 656 868  
rhopkins@zeldatherapeutics.com

Monsoon Communications  
Rudi Michelson  
+61 3 9620 3333  
rudim@monsoon.com

**Directors**

Dr Richard Hopkins  
Mr Harry Karelis  
Dr Stewart Washer  
Ms Mara Gordon  
Mr Jason Peterson

**Tickers:**

Australia (ASX): ZLD  
USA (OTCQB): ZLDAF

**Ordinary Shares:**

755,341,934

**Options:**

49,000,000

1,500,000 (\$0.04 – 6/2/2020)  
\*4,500,000 (\$0.04 – 6/2/2020)  
1,000,000 (\$0.125 – 22/8/2021)  
\*2,000,000 (\$0.125 – 22/8/2021)

40,000,000 (\$0.03125 – 17/11/2021)

*\* subject to vesting conditions*

## Correction to unlisted option expiry date

**Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF)** refers to ASX Notice - Reinstatement to Official Quotation dated 18 November 2016 (**Notice**). Due to an administrative error, the Notice advised an incorrect expiry date for 40,000,000 unlisted options exercisable at \$0.03125.

The Appendix 3B lodged by the Company on 17 November 2016 correctly stated the expiry date, which was 5 years after the date of issue, as 17 November 2021.

**Tim Slate**  
**Company Secretary**

**About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-armed strategy comprising:

- A **human clinical trial programme** focused on insomnia & autism with activities in Australia and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.